We’re pleased to share that the first patient has been dosed in REVITALYZ™, a Phase 3 clinical trial evaluating the safety and efficacy of a potential treatment for idiopathic hypersomnia (IH), a sleep disorder characterized by excessive sleep and daytime sleepiness. “We are committed to advancing this trial and are emboldened by the excitement of experienced clinical trial sites’ participation, which reflects the critical unmet need in the current landscape.” - Jennifer Gudeman Learn more: https://lnkd.in/gMpNkZBK
This is good news
I am so excited to hear this!!!
Medical writer and editor
2moSo excited to hear this! Once-nightly dosing of sodium oxybate is such a fabulous opportunity for folks with IH.